Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2010 2
2011 1
2012 1
2013 3
2014 7
2015 4
2016 3
2017 2
2018 6
2019 5
2020 5
2021 11
2022 21
2023 34
2024 27
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, Wernli KJ, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber ZA, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Frutos AM, et al. Among authors: tartof sy. MMWR Morb Mortal Wkly Rep. 2024 Feb 29;73(8):168-174. doi: 10.15585/mmwr.mm7308a3. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38421935 Free PMC article.
Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19.
Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, Stern JA, Zamparo J, Simmons S, Jodar L, McLaughlin JM. Tartof SY, et al. JAMA Intern Med. 2024 Aug 1;184(8):932-940. doi: 10.1001/jamainternmed.2024.1640. JAMA Intern Med. 2024. PMID: 38913355 Free PMC article.
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.
Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, Liu Q, Shaw S, Welsh S, Stern JA, Kapadia B, Spence BC, Lewnard JA, Davis GS, Aragones M, Dutro M, Chilson E, Gonzalez E, Hubler R, Chia B, Jodar L, Gessner BD, Begier E. Tartof SY, et al. JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832. JAMA Netw Open. 2024. PMID: 39671195 Free PMC article.
Wildfire Smoke Exposure and Incident Dementia.
Elser H, Frankland TB, Chen C, Tartof SY, Mayeda ER, Lee GS, Northrop AJ, Torres JM, Benmarhnia T, Casey JA. Elser H, et al. Among authors: tartof sy. JAMA Neurol. 2025 Jan 1;82(1):40-48. doi: 10.1001/jamaneurol.2024.4058. JAMA Neurol. 2025. PMID: 39585704
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025.
Frutos AM, Cleary S, Reeves EL, Ahmad HM, Price AM, Self WH, Zhu Y, Safdar B, Peltan ID, Gibbs KW, Exline MC, Lauring AS, Ball SW, DeSilva M, Tartof SY, Dascomb K, Irving SA, Klein NP, Dixon BE, Ong TC, Vaughn IA, House SL, Faryar KA, Nowalk MP, Gaglani M, Wernli KJ, Murugan V, Williams OL, Selvarangan R, Weinberg GA, Staat MA, Halasa NB, Sahni LC, Michaels MG, Englund JA, Kirby MK, Surie D, Dawood FS, Clopper BR, Moline HL, Link-Gelles R, Payne AB, Harker E, Wielgosz K, Weber ZA, Yang DH, Lewis NM, DeCuir J, Olson SM, Chung JR, Flannery B, Grohskopf LA, Reed C, Garg S, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Frutos AM, et al. Among authors: tartof sy. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):83-90. doi: 10.15585/mmwr.mm7406a2. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014791 Free PMC article.
Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection.
Malden DE, Liu IA, Qian L, Sy LS, Lewin BJ, Asamura DT, Ryan DS, Bezi C, Williams JTB, Kaiser R, Daley MF, Nelson JC, McClure DL, Zerbo O, Henninger ML, Fuller CC, Weintraub ES, Saydah S, Tartof SY. Malden DE, et al. Among authors: tartof sy. Nat Commun. 2024 May 22;15(1):4101. doi: 10.1038/s41467-024-48022-9. Nat Commun. 2024. PMID: 38778026 Free PMC article.
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.
Tartof SY, Slezak JM, Puzniak L, Frankland TB, Ackerson BK, Jodar L, McLaughlin JM. Tartof SY, et al. Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39015348 Free PMC article.
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.
Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY. Lewnard JA, et al. Among authors: tartof sy. Nat Commun. 2023 Jun 29;14(1):3854. doi: 10.1038/s41467-023-39567-2. Nat Commun. 2023. PMID: 37386005 Free PMC article.
134 results